| Topic | Key points | Best recent source(s) with publication year and URL | Evidence citation IDs |
|---|---|---|---|
| Definition and spectrum | EEC/BEEC is a congenital malformation spectrum involving the abdominal wall, bony pelvis, urinary tract, external genitalia, and in severe cases the gastrointestinal tract. Severity runs from epispadias (mildest) to classic bladder exstrophy/CBE (intermediate, most common) to cloacal exstrophy/CE (most severe). | Köllges et al., 2023, *Biomolecules*, https://doi.org/10.3390/biom13071117; Kolvenbach et al., 2023, *Molecular and Cellular Pediatrics*, https://doi.org/10.1186/s40348-023-00156-4 | (pqac-00000005, pqac-00000017, pqac-00000025) |
| Epidemiology | Reported incidences: epispadias ~2 per 100,000; bladder exstrophy ~4 per 100,000; cloacal exstrophy ~0.5–1 per 100,000. Other reports give E ~2.4:100,000, CBE ~1–2:50,000, CE ~0.5–1:200,000; overall European birth prevalence ~1:10,000. Epispadias and bladder exstrophy are more common in males, whereas cloacal exstrophy is more common in females. | Brockwell et al., 2024, *Cells*, https://doi.org/10.3390/cells13221866; Köllges et al., 2023, *Biomolecules*, https://doi.org/10.3390/biom13071117 | (pqac-00000013, pqac-00000005) |
| Embryology and pathophysiology | Leading developmental model: overdevelopment/persistence of the cloacal membrane impairs mesenchymal migration, predisposing to rupture; rupture timing relative to urorectal septation may influence phenotype (CE if earlier, epispadias if later). Additional embryologic mechanisms include abnormal pelvic ring formation, disrupted cloacal patterning, apoptosis gradients, and SHH→BMP4→SMAD epithelial–mesenchymal signaling relevant to bladder smooth-muscle differentiation. | Brockwell et al., 2024, *Cells*, https://doi.org/10.3390/cells13221866; Mingardo GWAS/thesis text, URL not available in retrieved metadata | (pqac-00000013, pqac-00000004) |
| Core genetic architecture | Genetics is heterogeneous and incompletely resolved. Recurrent 22q11.2/22q11.21 microduplication is the most established recurrent CNV risk factor (~2–3% of cases in prior literature). Candidate/susceptibility genes implicated across studies include ISL1, LZTR1, WNT3, WNT9B, TP63, SLC20A1, and possibly SLC7A4; rare/common variation both contribute. | Nordenskjöld et al., 2023, *Am J Med Genet A*, https://doi.org/10.1002/ajmg.a.63031; Brockwell et al., 2024, *Cells*, https://doi.org/10.3390/cells13221866; Chan et al., 2024, medRxiv, https://doi.org/10.1101/2024.10.10.24315242 | (pqac-00000000, pqac-00000002, pqac-00000013, pqac-00000003) |
| 2023 exome/resequencing findings | In CE trios, exome analysis identified de novo candidate genes NR1H2 and GKAP1, biallelic candidates AKR1B10, CLSTN3, NDST4, PLEKHB1, and suggestive UPD involving SVEP1; follow-up resequencing did not find additional carriers. In the 22q11.2 phenocritical region, two independent CBE males carried frameshift variants in LZTR1 (c.978_985del, p.Ser327fs*6) and SLC7A4 (c.1087delC, p.Arg363fs*68), further implicating LZTR1. | Köllges et al., 2023, *Biomolecules*, https://doi.org/10.3390/biom13071117 | (pqac-00000005, pqac-00000006, pqac-00000008, pqac-00000010) |
| CNV burden and pathways | In a cohort of 140 bladder exstrophy patients, pathogenic/possibly pathogenic CNVs were found in 16 (11.4%), with 9 additional VUS. Data support involvement of WNT signaling, the chromosome 22q11 region, RIT2/POU-family networks, and Golgi/vesicle trafficking pathways. | Nordenskjöld et al., 2023, *Am J Med Genet A*, https://doi.org/10.1002/ajmg.a.63031 | (pqac-00000000, pqac-00000016) |
| GWAS and common-variant evidence | Prior large European GWAS identified ISL1 as a replicated susceptibility locus. A later sequencing-based GWAS/meta-analysis in 97 CBE cases vs 22,037 controls found no new robust loci after replication/meta-analysis, but replicated the ISL1 locus (rs9291768, P=1.48×10^-3, OR 1.62) and identified a rare intergenic indel rs550737686 (P=2.35×10^-5, OR 6.11). Mingardo’s larger GWAS resource summarized 628 cases and 7,352 controls and reported eight genome-wide significant loci. | Chan et al., 2024, medRxiv, https://doi.org/10.1101/2024.10.10.24315242; Mingardo GWAS/thesis text, URL not available in retrieved metadata | (pqac-00000003, pqac-00000001, pqac-00000015) |
| Functional/model-organism evidence | Zebrafish studies support developmental roles for candidate genes: wnt3 knockdown causes cloacal defects, and slc20a1a knockdown impairs cloacal excretory function with hindgut distension. Zebrafish are useful because of rapid development, transparent larvae, and CRISPR/Morpholino tractability, though they lack a true human bladder/genital anatomy. | Kolvenbach et al., 2023, *Molecular and Cellular Pediatrics*, https://doi.org/10.1186/s40348-023-00156-4 | (pqac-00000017, pqac-00000018, pqac-00000019) |
| Diagnostics | Diagnosis is primarily clinical postnatally and by prenatal imaging antenatally. Recent case literature supports targeted prenatal ultrasound with confirmation by fetal MRI in suspected fetal bladder exstrophy; multidisciplinary prenatal counseling/referral is emphasized. Genetic testing can include chromosomal microarray/CNV analysis and research-grade exome/genome approaches given heterogeneous etiology. | Zhan et al., 2024, *BMC Pregnancy and Childbirth*, https://doi.org/10.1186/s12884-024-06318-0; Nordenskjöld et al., 2023, *Am J Med Genet A*, https://doi.org/10.1002/ajmg.a.63031; Köllges et al., 2023, *Biomolecules*, https://doi.org/10.3390/biom13071117 | (pqac-00000020, pqac-00000000, pqac-00000010) |
| Standard treatment strategy | Management is surgical and often staged. Common primary paradigms are modern staged repair of exstrophy (MSRE) and complete primary repair of exstrophy (CPRE). Additional continence operations are frequently needed, including bladder neck reconstruction (BNR), augmentation cystoplasty (AC), continent catheterizable stoma, or bladder neck closure (BNC) with continent diversion. | Song et al., 2025, *American Journal of Translational Research*, https://doi.org/10.62347/uyra1911 | (pqac-00000024) |
| Outcomes and prognosis | Functional outcomes remain variable. Only ~23% may achieve volitional voiding with dry interval ≥3 h after initial repairs alone, while continence can rise to ~93% after combined continence procedures over long-term follow-up. Around 40% may still require catheterization after CPRE; adulthood renal morbidity is important, with one cited cohort showing 44% stage II+ CKD. Long-term sexual/fertility challenges are also common. | Song et al., 2025, *American Journal of Translational Research*, https://doi.org/10.62347/uyra1911 | (pqac-00000024) |
| Current interventional research | Two illustrative ongoing/modern interventional directions are: ACT balloons for sphincteric incontinence in bladder exstrophy/epispadias (primary endpoint: ≥50% reduction in 24-h pad weight at 6–24 months; NCT04935918), and autologous platelet-rich fibrin adjunct at primary repair to reduce penopubic fistula/wound dehiscence (20-patient randomized study; NCT07294612). | ClinicalTrials.gov NCT04935918, https://clinicaltrials.gov/study/NCT04935918; ClinicalTrials.gov NCT07294612, https://clinicaltrials.gov/study/NCT07294612 | (pqac-00000021, pqac-00000020, pqac-00000022) |


*Table: This table compacts the most decision-relevant facts on Exstrophy–Epispadias Complex, including spectrum definition, epidemiology, genetics, diagnostics, treatment, and outcomes. It is useful as a quick-reference evidence map tied to recent primary and review sources plus trial records.*